- Home
- AIRI vs LGVN Comparison
AIRI vs LGVN Comparison
Compare AIRI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- LGVN
- Stock Information
- Founded
- AIRI 1979
- LGVN 2014
- Country
- AIRI United States
- LGVN United States
- Employees
- AIRI N/A
- LGVN N/A
- Industry
- AIRI Military/Government/Technical
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- AIRI Industrials
- LGVN Health Care
- Exchange
- AIRI Nasdaq
- LGVN Nasdaq
- Market Cap
- AIRI 15.2M
- LGVN 16.6M
- IPO Year
- AIRI N/A
- LGVN 2021
- Fundamental
- Price
- AIRI $3.22
- LGVN $0.75
- Analyst Decision
- AIRI
- LGVN Strong Buy
- Analyst Count
- AIRI 0
- LGVN 2
- Target Price
- AIRI N/A
- LGVN $6.50
- AVG Volume (30 Days)
- AIRI 67.0K
- LGVN 2.0M
- Earning Date
- AIRI 08-14-2025
- LGVN 08-13-2025
- Dividend Yield
- AIRI N/A
- LGVN N/A
- EPS Growth
- AIRI N/A
- LGVN N/A
- EPS
- AIRI N/A
- LGVN N/A
- Revenue
- AIRI $52,277,000.00
- LGVN $2,073,000.00
- Revenue This Year
- AIRI N/A
- LGVN N/A
- Revenue Next Year
- AIRI $4.99
- LGVN $10.78
- P/E Ratio
- AIRI N/A
- LGVN N/A
- Revenue Growth
- AIRI N/A
- LGVN 68.67
- 52 Week Low
- AIRI $2.80
- LGVN $0.63
- 52 Week High
- AIRI $7.41
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- AIRI 49.40
- LGVN 32.11
- Support Level
- AIRI $3.13
- LGVN $0.80
- Resistance Level
- AIRI $3.37
- LGVN $0.87
- Average True Range (ATR)
- AIRI 0.12
- LGVN 0.05
- MACD
- AIRI 0.02
- LGVN 0.02
- Stochastic Oscillator
- AIRI 73.68
- LGVN 16.79
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.